Guwahati

M.Pharm / MS Pharm Pharmaceutical Analysis / Quality Assurance)/ Natural Products / Medicinal Chemistry / MSc in analytical chemistry or Organic Chemistry from a PCI/AICTE/UGC/NAAC recognized

Ph.D. at the preceding M.Sc, M.Pharm, M.S.Pharm, B.Tech, M.Tech in Biomedical engineering, Medical devices.

Masters degree in any areas of Life Sciences or Pharmacy/ Pharmacology with first class or equivalent in terms of Grades or marks at the preceding degree and excellent academic record throughout. 

M.Sc. in Chemistry, Biochemistry, Pharmaceutical Chemistry, Sciences or M.Pharm. with five years research experience. 3 years research experience in natural products, synthesis, analysis of organic compounds, bio-chemical, pharmaceutical sciences and experience in testing of tobacco products at any nationalized tobacco testing laboratory.

Method transfer of Pharmaceuticals Products and Materials. Analysis of In-process, Finished products, Stability study samples and raw material. Sampling and testing of Raw Materials, Packaging Materials and Water samples. Calibration and Handling of Laboratory Instruments like - GC, HPLC and Autotitrator etc

Pursuing B.Sc, B.Tech, B.Pharma Microbiology, Biotechnology any branch of Life Sciences; M.Sc, M.Tech, M.Pharm Microbiology, Biotechnology any branch of Life Sciences.

First class Post Graduate Degree, including the integrated PG degrees in the area of Pharmacology and Toxicology, Life sciences, Biotechnology, Molecular biology, Immunology, Zoology or equivalent with one year of experience.

Candidates shall be eligible to apply for admission and registration within the ongoing program of research at IASST, if he, she has obtained 55% marks in aggregate Equivalent CGPA in 10-point scale in the master’s degree examination.

Dr. B. Borooah Cancer Institute, Guwahati is hiring following staff on contractual basis for Dr Reddy’s Laboratories supported trial A phase 4. multicenter, non-comparative, open-iabel. two cohort study evaluating the safety and efficacy of intravenously administered toripalimab in the treatment of Indian patients with recurrent or metastatic nasopharyngeal carcinoma.